Role of (18)F-fluorodeoxyglucose Positron Emission Tomography scan in differentiating enhancing brain tumors

AIM: To determine whether F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) can be used to differentiate among common enhancing brain tumors such as gliomas, metastatic brain tumors, and lymphoma. MATERIALS AND METHODS: We evaluated 20 patients with an enhancing brain tumor on magnetic resonance imaging (MRI). FDG PET scan was done in all patients pre operatively. For PET image analysis, regions of interest were placed over the tumor (T), contralateral cortex (C), and white matter (WM). Average and maximum pixel values were determined at each site. On the basis of these measurements, average and maximum standard uptake values (SUV (avg) and SUV (max) ) were calculated, and comparisons among lesions were then made. RESULTS: SUV(avg) and SUV(max) are significantly higher for central nervous system (CNS) lymphoma than for other tumors (P < 0.01). High-grade gliomas showed significantly higher SUV(avg) and SUV(max) than the low grade gliomas (P < 0.05) and metastatic tumor showed higher SUV(avg) and SUV(max) than all gliomas, both low and high grade (P < 0.05). When the lowest values of CNS lymphoma parameter were used as cutoff levels to distinguish CNS lymphomas from other tumors (i.e. 100% sensitivity), SUV(max) was the most accurate parameter. Using a SUV(max) of 15.0 as a cutoff for diagnosing CNS lymphoma, only one case of metastasis (SUV (max) , 16.3) was found to be false positive in this study. CONCLUSION: FDG PET appears to provide additional information for differentiating common enhancing malignant brain tumors, namely lymphoma versus high grade glioma and metastatic tumor, particularly when differential diagnoses are difficult to narrow using MRI alone.